Seeking Alpha
 

Covidien plc (COV)

- NYSE
  • Jul. 2, 2013, 7:35 AM
    The IRS has disallowed $2.86B in interest and deductions that Tyco (TYC) recognized for the 1997-2000 tax years. The move follows an inquiry which found that some of the firm's former subsidiaries owe 883.3M in taxes and $154M in penalties. Tyco disagrees with IRS's claims and intends to go to court over them. Former Tyco units that are caught up in the issue and that could face liabilities include Covidien (COV), TE Connectivity (TEL), ADT (ADT) and Pentair (PNR).
    | Comment!
  • Jul. 1, 2013, 12:45 PM
    Midday top 10 gainers: ONXX +51%. SPEX +24%. ACUR +19%. LVB +15%. DM +15%. ARIA +14%. HNR +13%. AXU +13%. TRT +11%. ATAI +11%.
    Midday top 10 Losers: NWSA -54%. INSM -15%. DSS -15%. IDCC -14%. TXMD -12%. HDY -13%. NTS -11%. PME -10%. ALVR -9%. COV -8%.
    | 2 Comments
  • Jul. 1, 2013, 7:23 AM
    Covidien (COV -7.5%) has completed the separation of its pharmaceuticals business, called Mallinckrodt, which will begin regular trading on the NYSE today under the symbol MNK. Mallinckrodt issued one share for every eight Covidien shares held on June 19. Covidien is left with its medical devices and supplies operations. (PR)
    | Comment!
  • Jun. 20, 2013, 8:47 AM
    Covidien's (COV) Kendall SCD system helped cut the development of deep vein thrombosis (DVT) in immobile stroke patients by 29.9% in an independent study of 2,876 subjects. The system also reduced the risk of death by 14% in the six months after an attack. The device works by squeezing the leg gently to increase blood flow and help prevent DVTs, which are blood clots that can form in the leg, travel to the lungs and cause death. (PR)
    | Comment!
  • Jun. 17, 2013, 7:39 AM
    Covidien (COV) publishes the final results of the pivotal trial for its Pipeline embolization device for the treatment of patients with an unruptured large or giant wide-necked aneurysm in Radiology, the official peer-reviewed journal of the Radiological Society. Data from this trial led the FDA to approve the treatment in 2011. (PR)
    | Comment!
  • May 24, 2013, 7:30 AM
    Some details for Covidien's (COV) pharmaceuticals business spin-off (previous): Shareholders will receive one share of the new publicly traded company (Mallinckrodt) for every eight shares of COV they own. Mallinckrodt is expected to begin trading on the NYSE on July 1 (ticker: MNK). (PR)
    | 3 Comments
  • May 21, 2013, 2:05 PM
    Given Imaging (GIVN -1.2%) gives back early morning gains after presenting new studies that confirm the value of its PillCam SB in the diagnosis, monitoring and management of Crohn's Disease and other small bowel conditions in patients at this year's Digestive Disease Week in Orlando, Florida. Trial data shows heightened sensitivity for detecting adenomas that are at least 6 mm and 10 mm.
    | Comment!
  • May 20, 2013, 2:17 PM
    Covidien (COV -0.1%) says its Nellcor pulse oximetry portfolio has received FDA 501(k) clearance for motion claims. COV is the first company of its kind to receive the FDA stamp of approval for a motion-tolerant bedside device that's also compliant with the International Organization for Standardization standards for pulse oximetry.
    | Comment!
  • May 20, 2013, 8:50 AM
    Given Imaging (GIVN) rises 2.34% premarket after saying several studies presented at Digestive Disease Week highlight the value of the company's SmartPill for the "evaluation and diagnosis of different motility conditions." The studies suggest "an expanded role" for the device, the company says. (PR)
    | Comment!
  • May 8, 2013, 4:44 PM
    Given Imaging (GIVN): Q1 EPS of $0.06 misses by $0.07. Revenue of $40.6M misses by $4.03M. (PR)
    | Comment!
  • May 3, 2013, 5:17 PM
    Covidien (COV) reduces its FY13 net sales guidance and adjusts its financial statements for the past three years to refect the impending spinoff of its Malinckrodt business. The company now estimates that net sales in FY13 will be up 4% to 5%, which corresponds to about $12.32B to $12.44B, down from its prior projection of 5% to 8% growth. It expects Mallinckrodt to see sales growth of between 7% to 11% for the fiscal year ending September 27. Shares -0.5% AH.
    | Comment!
  • Apr. 26, 2013, 6:01 AM
    Covidien (COV): FQ2 EPS of $1.12 beats by $0.03. Revenue of $3.10B (+5% Y/Y) misses by $0.02B. (PR)
    | Comment!
  • Apr. 26, 2013, 12:05 AM
    Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY
    | Comment!
  • Apr. 25, 2013, 5:30 PM
    Notable earnings before Friday’s open: ABBV, AEP, AON, ARLP, B, BKW, BPO, COV, CVX, DHI, DLR, DTE, FLIR, GDI, GNC, GT, HMSY, IMGN, ITRI, LAZ, LYB, MPW, NOV, SPG, TRP, TYC, VFC, VTR, WETF, WY
    | Comment!
  • Apr. 11, 2013, 12:37 PM
    Covidien (COV +1.1%) says it's entered into an agreement with VIDA Diagnostics to distribute it's Apollo pulmonary imaging software services. The agreement enables COV to offer a combination of technologies from VIDA and Covidien's i-Logic lung navigation system, which provides physicians with enhanced detail for the minimally invasive diagnosis and treatment planning of a variety of lung diseases.
    | Comment!
  • Apr. 1, 2013, 9:09 AM
    Medical products maker Covidien (COV) says it was awarded $176M as a federal court ruled several patents were infringed by Johnson & Johnson's (JNJ) Ethicon Endo-Surgery unit and its Harmonic line of ultrasonic surgical products.
    | Comment!
Visit Seeking Alpha's
COV vs. ETF Alternatives
Company Description
Covidien PLC is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's business segments are Medical Devices and U.S Medical Supplies.